Sosei, Allergan Suspend Joint Clinical Development of AD Therapy due to Unexpected Toxicology Findings

Sosei Group and Allergan will voluntarily suspend clinical development of HTL0018318 (development code), a selective small molecule muscarinic M1 receptor agonist under development by the two companies for the treatment of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB),...read more